Eosinophilic Esophagitis - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
60 Pages - GMD12054
$2,000.00

Summary

Global Markets Direct’s, ‘Eosinophilic Esophagitis - Pipeline Review, H1 2014’, provides an overview of the Eosinophilic Esophagitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Eosinophilic Esophagitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Eosinophilic Esophagitis Overview 7
Therapeutics Development 8
Pipeline Products for Eosinophilic Esophagitis - Overview 8
Pipeline Products for Eosinophilic Esophagitis - Comparative Analysis 9
Eosinophilic Esophagitis - Therapeutics under Development by Companies 10
Eosinophilic Esophagitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Eosinophilic Esophagitis - Products under Development by Companies 16
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 17
Novartis AG 17
Aptalis Pharma Inc. 18
Teva Pharmaceutical Industries Limited 19
DBV Technologies 20
Meritage Pharma, Inc. 21
Oxagen Limited 22
Dr. Falk Pharma GmbH 23
Receptos, Inc. 24
Lipella Pharmaceuticals, Inc. 25
Eosinophilic Esophagitis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
reslizumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
OC-459 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
budesonide - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
QAX-576 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RPC-4046 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
EUR-1100 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Drug for Eosinophilic Esophagitis - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
tacrolimus liposomal - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
budesonide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Eosinophilic Esophagitis - Recent Pipeline Updates 50
Eosinophilic Esophagitis - Dormant Projects 54
Eosinophilic Esophagitis - Product Development Milestones 55
Featured News & Press Releases 55
Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 55
May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 55
May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 56
Nov 23, 2009: Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables
Number of Products under Development for Eosinophilic Esophagitis, H1 2014 8
Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Comparative Analysis by Unknown Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Eosinophilic Esophagitis - Pipeline by Novartis AG, H1 2014 17
Eosinophilic Esophagitis - Pipeline by Aptalis Pharma Inc., H1 2014 18
Eosinophilic Esophagitis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 19
Eosinophilic Esophagitis - Pipeline by DBV Technologies, H1 2014 20
Eosinophilic Esophagitis - Pipeline by Meritage Pharma, Inc., H1 2014 21
Eosinophilic Esophagitis - Pipeline by Oxagen Limited, H1 2014 22
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2014 23
Eosinophilic Esophagitis - Pipeline by Receptos, Inc., H1 2014 24
Eosinophilic Esophagitis - Pipeline by Lipella Pharmaceuticals, Inc., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 32
Number of Products by Stage and Route of Administration, H1 2014 34
Number of Products by Stage and Molecule Type, H1 2014 36
Eosinophilic Esophagitis Therapeutics - Recent Pipeline Updates, H1 2014 50
Eosinophilic Esophagitis - Dormant Projects, H1 2014 54

List of Figures
Number of Products under Development for Eosinophilic Esophagitis, H1 2014 8
Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 33
Number of Products by Stage and Top 10 Route of Administration, H1 2014 34
Number of Products by Top 10 Molecule Type, H1 2014 35
Number of Products by Stage and Top 10 Molecule Type, H1 2014 36

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax